# ISM4808

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/ism4808
Canonical HTML page: https://gethealthbrief.com/entity/ism4808

## Timeline

- **2026-03-06**: Phase I Milestone — First human subject enrolled and dosed in the Phase I clinical trial.
- **2026**: AI Discovery — Insilico Medicine identifies ISM4808 using its Pharma.AI platform.
- **2025**: Out-Licensing — TaiGen Biotechnology secures rights for the clinical development of the candidate.

## Recent coverage (1 stories)

### Insilico and TaiGen Advance AI-Derived CKD Anemia Drug to Phase I Trials
2026-03-06 12:39:16 · Sentiment: Positive · Impact: 6/10 · Sources: 3

Insilico Medicine and TaiGen have successfully enrolled and dosed the first human subject in a Phase I clinical trial for ISM4808, a novel drug candidate for Chronic Kidney Disease (CKD) anemia. The milestone validates the clinical transition of an AI-discovered molecule under a strategic out-licensing agreement.
Full story: https://gethealthbrief.com/story/insilico-taigen-ckd-anemia-phase-i-milestone

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.